OptimizeRx Corporation
OPRX
$6.50
$0.071.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.24M | 26.07M | 29.20M | 21.93M | 32.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.24M | 26.07M | 29.20M | 21.93M | 32.32M |
| Cost of Revenue | 8.14M | 8.55M | 10.56M | 8.58M | 10.29M |
| Gross Profit | 24.10M | 17.52M | 18.64M | 13.34M | 22.02M |
| SG&A Expenses | 14.09M | 14.39M | 14.37M | 14.36M | 17.05M |
| Depreciation & Amortization | 1.08M | 1.08M | 1.07M | 1.09M | 1.09M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.30M | 24.02M | 26.01M | 24.04M | 28.44M |
| Operating Income | 8.94M | 2.05M | 3.19M | -2.11M | 3.88M |
| Income Before Tax | 7.47M | 1.05M | 1.71M | -3.28M | 2.21M |
| Income Tax Expenses | 2.45M | 270.00K | 181.00K | -1.09M | 2.29M |
| Earnings from Continuing Operations | 5.02M | 779.00K | 1.53M | -2.20M | -78.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.02M | 779.00K | 1.53M | -2.20M | -78.00K |
| EBIT | 8.94M | 2.05M | 3.19M | -2.11M | 3.88M |
| EBITDA | 10.44M | 2.99M | 4.13M | -1.17M | 5.38M |
| EPS Basic | 0.27 | 0.04 | 0.08 | -0.12 | 0.00 |
| Normalized Basic EPS | 0.26 | 0.04 | 0.06 | -0.11 | 0.08 |
| EPS Diluted | 0.25 | 0.04 | 0.08 | -0.12 | 0.00 |
| Normalized Diluted EPS | 0.25 | 0.03 | 0.06 | -0.11 | 0.08 |
| Average Basic Shares Outstanding | 18.66M | 18.58M | 18.51M | 18.47M | 18.42M |
| Average Diluted Shares Outstanding | 19.38M | 19.46M | 19.02M | 18.47M | 18.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |